Skip to main content

Escientia establishes subsidiary in the Basel Area

| News

Escientia establishes subsidiary in the Basel Area


The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer services to innovators and biotech startups at its Schweizerhalle facility.

Escientia's logo being assembled in Schweizerhalle (img: Escientia)

The new Escientia Switzerland subsidiary of the Escientia Life Sciences Group is based in Schweizerhalle, the industrial complex in the municipalities of Muttenz and Pratteln. The U.S. company offers services in the areas of drug discovery, development, production and commercialization. In the Getec Park in Schweizerhalle, Escientia has newly acquired a plant previously operated by Novartis. The investment and innovation promotion agency Basel Area Business & Innovation as well as the Standortförderung Baselland supported Escientia in establishing the subsidiary (read more about starting a business in Switzerland).

Escientia Switzerland will invest a two-digit million Swiss franc amount to modernize the plant and install manufacturing facilities for drug substance production. The 17,000 square meter site will then be providing services to large innovators and biotech startups in the Basel Area.

Alongside the various life sciences companies in the region that might be potential customers of Escientia, the U.S. company will also benefit from the highly qualified employees that the Basel Area has to offer. For this year alone, the creation of approximately 60 jobs is planned.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.